국내외 이상지질혈증 치료지침의 비교 및 한국인에서의 치료지침의 적절성 = The Comparison of Guidelines for Management of Dyslipidemia and the Appropriateness of Them in Korea

다국어 초록 (Multilingual Abstract)

There have been accumulating evidences that dyslipidemia is a major risk factor of cardiovascular disease (CVD) and improvement in lipid profile can reduce the incidence of CVD. Guidelines for management of dyslipidemia have been developed by major organizations in several contries including the United States. In Korea, a guideline was also published by the Korean Society of Lipidology and Atherosclerosis. However, This guideline was not based on evidences in Korea,but was made by a consensus of experts using a pre-developed guideline as a reference. For clinical application for Korean of guidelines developed in different nations, the disease epidemiology and medical environment in Korea should be considered. In this article, we reviewed whether guidelines for management of dyslipidemia are applicable in Korean context.

국문 초록 (Abstract)

이상지질혈증이 심혈관질환의 중요한 위험인자이며, 혈중 지질 농도의 개선을 통해 심혈관질환을 예방할 수 있다는 사실이 밝혀지면서, 미국을 비롯한 세계의 여러 나라에서 이상지질혈증의 개선을 통해 심혈관질환을 예방하기 위한 근거 중심 치료지침들을 발표하고 있다. 우리나라에서도 한국지질동맥경화학회를 중심으로 이상지질혈증 치료지침을 발표하였으나, 치료지침을 구체화할 만한 한국인을 대상으로 한 연구결과가 부족하여, 외국의 치료지침을 참고하여 전문가들의 의견을 모아 치료기준을 정하고 있다. 외국의 치료지침을우리나라에 적용하기 위해서는 우리나라의 질병 발생양상 및의료환경 등을 먼저 고려해야 한다. 이에 우리나라의 심혈관질환의 역학적 특성을 검토하여 국내외의 이상지질혈증 치료지침들이 한국인에게 적절한지를 평가하였으며, 이와 함께건강보험심사평가원의 지질저하제 처방 심사기준의 문제점에 대해서 살펴보았다.

참고문헌 (Reference)

• 1 김상현, "국내 병의원의 고콜레스테롤혈증 치료 현황" 대한심장학회 36 (36): 593-599, 2006
• 2 성지동, "국내 10개 대학병원의 관동맥질환자의 고콜레스테롤혈증 치료 현황" 대한내과학회 69 (69): 371-378, 2005
• 3 한기훈, "고지혈증의 유형에 따른 치료" 대한의사협회 52 (52): 299-311, 2009
• 4 Carroll MD, "Trends in serum lipids and lipoproteins of adults, 1960-2002" 294 : 1773-1781, 2005
• 5 Koba S, "Treatment of hyperlipidemia from Japanese evidence" 13 : 267-280, 2006
• 6 Okamura T, "The relationship between serum total cholesterol and all-cause or cause-specic mortality in a 17.3-year study of a Japanese cohort" 190 : 216-223, 2007
• 7 World Health Organization, "The global burden of disease: 2004 update"
• 8 Korea Centers for Disease Control and Prevention, "The Third Korea National Health and Nutrition Examination Survey (KHANES III)"
• 9 Korea Centers for Disease Control and Prevention, "The Fourth Korea National Health and Nutrition Examination Survey (KHANES IV-1), 2007"
• 10 "Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)" 269 : 3015-3023, 1993
• 11 Vergouwen MD, "Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease" 39 : 497-502, 2008
• 12 Jee SH, "Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol: the Korea Medical Insurance Corporation Study" 282 : 2149-2155, 1999
• 13 Liao JK, "Safety and efficacy of statins in Asians" 99 : 410-414, 2007
• 14 "Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: the Expert Panel" 148 : 36-69, 1988
• 15 Prevention of coronary heart disease in clinical practice, "Recommendations of the Second Joint Task Force of European and other societies on coronary prevention" 19 : 1434-1503, 1998
• 16 Genest J, "Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update" 169 : 921-924, 2003
• 17 Fodor JG, "Recommendations for the management and treatment of dyslipidemia: report of the Working Group on Hypercholesterolemia and Other Dyslipidemias" 162 : 1441-1447, 2000
• 18 Kim SH, "Recent trend of management of hyperlipidemia and achievement of lipid treatment goals" 26 (26): 450-457, 2005
• 19 Pyorala K, "Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension" 110 : 121-161, 1994
• 20 Kim SH, "Perspective for improvement in the treatment of dyslipidemia in Korea" 19 : 155-160, 2009
• 21 LaRosa JC, "Past, present, and future standards for management of dyslipidemia" 116 (116): 3-8, 2004
• 22 "National Heart Lung and Blood Institute. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel IV)" National Heart Lung and Blood Institute
• 23 Schunemann HJ, "Improving the use of research evidence in guideline development: 13. Applicability, transferability and adaptation" 4 : 25-, 2006
• 24 Grundy SM, "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines" 110 : 227-239, 2004
• 25 Wang A, "Ile118Val genetic polymorphism of CYP3A4 and its eects on lipid-lowering ecacy of simvastatin in Chinese hyperlipidemic patients" 60 : 843-848, 2005
• 26 Kim CJ, "Hypercholesterolemia: management of Korean patients in new millennium" 72 : 580-592, 2007
• 27 Committee for Establishing Treatment Instruction for Dyslipidemia of the Korean Society of Lipidology and Atherosclerosis, "Guidelines for management of dyslipidemia. 2nd ed" Korean Society of Lipidology and Atherosclerosis 2009
• 28 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)" 285 : 2486-2497, 2001
• 29 Teramoto T, "Executive summary of Japan Atherosclerosis Society ( JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese" 14 : 45-50, 2007
• 30 Park BJ, "Evidence-based healthcare. 1st ed" Korea Medical Publisher 2009
• 31 De Backer G, "European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)" 10 : 1-10, 2003
• 32 Graham I, "European guidelines on cardiovascular disease prevention in clinical practice: executive summary" 194 : 1-45, 2007
• 33 Lee BC, "Epidemiology of stroke in Korea" 45 : 1415-1421, 2002
• 34 Suh I, "Epidemiology of coronary heart disease" 26 : 11-15, 2006
• 35 Jee SH, "Development of the individualized health risk appraisal model of ischemic heart disease risk in Korea" 14 : 153-168, 2004
• 36 "Crestor (rosuvastatin calcium) Prescribing Information" AstraZeneca
• 37 Brownson RC, "Chronic disease epidemiology and control. 2nd ed" American Public Health Association 1998
• 38 Suh I, "Cardiovascular mortality in Korea: a country experiencing epidemiologic transition" 56 : 75-81, 2001
• 39 McPherson R, "Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-- recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease" 22 : 913-927, 2006
• 40 Korea National Statistical Oce, "Annual report on the cause of death statistics, 2007"
• 41 Genest J, "2009 Canadian Cardiovascular Society/ Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations" 25 : 567-579, 2009